# Aripiprazole Open-Label, Safety and Tolerability Study

> **NCT00102518** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 325 (actual)

## Conditions studied

- Schizophrenia
- Bipolar Disorder

## Interventions

- **DRUG:** Aripiprazole

## Key facts

- **NCT ID:** NCT00102518
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 325 (ACTUAL)
- **Last updated:** 2012-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00102518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00102518, "Aripiprazole Open-Label, Safety and Tolerability Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00102518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*